Liquidia Corporation (NASDAQ:LQDA) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET

Company Participants

Jason Adair - Chief Business Officer
Roger Jeffs - Chief Executive Officer
Rusty Schundler - General Counsel
Rajeev Saggar - Chief Medical Officer
Michael Kaseta - Chief Operating Officer & Chief Financial Officer
Scott Moomaw - Chief Commercial Officer

Conference Call Participants

Julian Harrison - BTIG
Jason Gerberry - Bank of America
Greg Harrison - Scotiabank
Kambiz Yazdi - Jefferies
Cory Jubinville - LifeSci Capital
Matt Kaplan - Ladenburg Thalmann
Ryan Deschner - Raymond James

Operator

Good morning and welcome everyone to Liquidia Corporation Third Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Michelle [ph] and I will be your conference operator today. Currently all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time to queue up for questions. I would like to remind everyone that this conference call is being recorded.

I would now like to hand the conference over to Jason Adair, Chief Business Officer. Please go ahead. Mr. Adair, you can go ahead.

Jason Adair

Thank you, Michelle [ph]. It's my pleasure to welcome everybody today to the Liquidia Corporation third quarter 2024 financial results and corporate update call. Joining the call today are Chief Executive Officer, Dr. Roger Jeffs; Chief Operating Officer and CFO, Michael Kaseta; Chief Medical Officer, Dr. Rajeev Saggar; Chief Commercial Officer, Scott Moomaw; and General Counsel, Rusty Schundler.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission which can be accessed on our website.

I'd now like to turn the call over to Roger for our prepared remarks, after which he will open the call for your questions.

Roger Jeffs

Good morning, everyone. We're pleased to be speaking with you today. With the significant progress made over the last few months, we now have a clear line of sight to seeking final approval of YUTREPIA for both PAH and PH-ILD patients. Final approval could occur following the expiration of TYVASO DPI's clinical exclusivity on May 23, 2025, or in just 6 months' time.